thyroid-associated ophthalmopathy
Conditions
Interventions
Protein A immunoadsorption:The first course of treatment involves protein A immunoadsorption every other day for 5 consecutive sessions. Record the therapeutic effect and administer the second course
model: WG-80-PP
source: Shandong Weigao Blood Purification Products Co., Ltd.), and a protein A immunoadsorption column (brand: Guangzhou Kangsheng, model: KCIA08, source: Guangzhou Kangsheng Biotechnology Co., Ltd.)
Methylprednisolone:500mg methylprednisolone powder injection is dissolved in 500mL of 5% glucose solution and administered intravenously once a day for 3 consecutive days
After a 3-day interval, repeat for another 3 days, and then take 60mg methylprednisolone tablets orally every day. Reduce by 10mg every 7 days until the medication is stopped. The accumulated amount o
Tocilizumab:Dissolve tocilizumab injection in 100mL of 0.9% sodium chloride solution, intravenously drip, with a single injection dose of 8mg/kg, once a month, for continuous treatment for 4-6 months.
Sponsors
The Third Xiangya Hospital, Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. TAO patients who meet the diagnostic criteria of TAO, refer to the BARTLEY diagnostic criteria, EUGOGO grading and CAScore, and are classified and staged as moderate to severe active phase. Independent statistical analysis of CAScores for both eyes, with the most severe eye as the study eye. A CAScore of >= 3 points is considered the active phase, and a CAScore of<3 points is considered the quiescent phase; 2. During the treatment period, no treatments such as orbital decompression, eyelid retraction, strabismus correction, orbital radiotherapy, or injection of hormones around or behind the ball were performed; 3. Thyroid function is basically under normal control.
Exclusion criteria
Exclusion criteria: 1. Combined inflammatory eye diseases, such as infectious keratitis, choroiditis, orbital cellulitis, etc; 2. Complicated with major systemic diseases, such as infectious diseases, autoimmune diseases, uncontrolled hypertension, poorly controlled diabetes, blood diseases, malignant tumors, liver and kidney dysfunction or severe trauma; 3. Pregnant women; 4. Severe mental illness and epilepsy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CAScore;Exophthalmos;Palpebral fissure width; | — |
Secondary
| Measure | Time frame |
|---|---|
| GO-QOL Score;Titer of thyroid related antibodies; | — |
Countries
China
Contacts
Public ContactXiong Wei
Department of Ophthalmology, The Third Xiangya Hospital, Central South University
Outcome results
None listed